Pharmacokinetic studies with recombinant hirudin in dogs
Research article published in Folia haematologica (Leipzig, Germany : 1928) (1988)
Abstract
The knowledge of the pharmacokinetics of recombinant hirudin is essential for potential clinical use of this selective thrombin inhibitor. For detailed information about absorption, distribution and elimination, pharmacokinetic studies with recombinant hirudin were carried out in dogs. The plasma concentration time curve after intravenous injection could be best described by an open two-compartment model with first order kinetics. The subcutaneous application of recombinant hirudin produced anticoagulantly effective blood level for a prolonged period of time. Recombinant hirudin is distributed into the extracellular space. This is also found in nephrectomized dogs. Recombinant hirudin is eliminated through the kidneys by glomerular filtration in active form with a half-life of 72 minutes.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed research on anticoagulant and antithrombotic drug development relevant to thrombin and factor inhibition. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This animal pharmacokinetic study characterized recombinant hirudin, the selective thrombin inhibitor originally derived from the medicinal leech, in dogs, finding that intravenous disposition fit a two-compartment first-order model, subcutaneous dosing produced prolonged anticoagulant blood levels, the drug distributed into the extracellular space, and it was eliminated by renal glomerular filtration in active form with a roughly 72-minute half-life. This is directly relevant to the leech-secretome drug-discovery story: it is foundational preclinical pharmacology establishing how the leech's signature anticoagulant behaves in vivo and informing the dosing rationale that underpinned later development of recombinant hirudins. Caveat: this is an early (1988) preclinical canine study of an isolated recombinant molecule, not a clinical trial and not a study of leech-applied hirudotherapy, so its parameters cannot be translated directly to human treatment.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026